Treatment Decisions in Localized Prostate Cancer: Patient, Partner, and Physician

2002 ◽  
Author(s):  
Katrina Armstrong
2019 ◽  
Author(s):  
Xiaojin Luo ◽  
Meilian Yi ◽  
Qun Hu ◽  
Weihua Yin

Abstract Objective:To evaluate the role of prostatectomy for localized prostate cancer patient. Methods: A systematic search was conducted using PubMed, and Web of Science through March 22, 2019 according to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to identify studies reporting on prostatectomy for localized prostate cancer patient. Results: Of a total of 1827 studies, 6 were considered for evidence synthesis. A total of 4476 patients in 4 studies were included for survival analysis, 2,779 patients received prostatectomy and 1,697 patients were received no treatment but regularly followed up. Two other studies were included for adverse effects analysis. Prostatectomy displayed a significantly decreased risk of death of 35% compared with observation (OR=0.65, 95%CI 0.53-0.81, P<0.0001). Pooled data indicated prostatectomy reduced 55% risk of disease progression (OR=0.45, 95% CI 0.34-0.60, P<0.00001). Anxiety, depressed mode, wellbeing, and sense of meaningfulness for patients were no difference between prostatectomy and observation group. However, prostatectomy increased 2.77 folds risk of erection dysfunction (OR=2.77, 95% CI, 1.60–4.81, P=0.0003 Conclusion: Prostatectomy prolonged survival and deferred disease progression compared to observation for localized prostate cancer patients. Symptoms between two groups were not significant difference except for erection function. Patients should decide prostatectomy or not after balancing the survival benefit and erection dysfunction.


Author(s):  
Jyoti Roy ◽  
Margaret E. White ◽  
Falguni Basuli ◽  
Ana Christina L. Opina ◽  
Karen Wong ◽  
...  

2021 ◽  
Author(s):  
Shubhangi Agarwal ◽  
donna.peehl not provided ◽  
Renuka Sriram

This protocol describes the steps required for the successful implantation of small cell neuroendocrine prostate cancer patient-derived xenograft (PDX) cells in the bone. Bone is one of the most common sites for the development of metastatic prostate cancer and its study is important for evaluating the tumor characteristics and response to therapy. This protocol can be used for the implantation of any tumor cell line in the bone.


Sign in / Sign up

Export Citation Format

Share Document